Back to mobile site

KeyBanc: 'We Highlight Danaher (DHR) Potential and EBITDA Upside'

December 18, 2025 7:24 AM EST Send to a Friend
KeyBanc analyst Paul Knight reiterated an Overweight rating and $310.00 price target on Danaher (NYSE: DHR).The analyst commented: "Life Science ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login